The activity reflects routine option exercise and modest monetization by executives, not a coordinated exit. Traders should monitor for any follow-up filings or news around earnings or pipeline updates, but this cluster alone does not signal material concern or optimism.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 18 $530.35entry
- T+1 · 8mo ago −0.63%α −0.39% · $527.00
- T+5 · 8mo ago +2.12%α +2.82% · $541.60
- T+20 · 7mo ago +9.46%α +3.38% · $580.51
- T+60 · 5mo ago +2.94%α −9.20% · $545.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Over the past seven days, key insiders at United Therapeutics, including CEO Martine Rothblatt and CFO James Edgemond, exercised stock options and conducted open-market sales totaling approximately $2.3 million in proceeds. The majority of transactions involved derivative exercises, with over $5.7 million in non-cash option exercises, while actual open-market sales amounted to $1.07 million.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt exercised options for 38,000 shares at $146.03 (total value: $5.57M) and sold 919 shares for $479,625 in open-market transactions.
- CFO James Edgemond exercised options for 10,000 shares at $135.42 (value: $1.35M) and sold 200 shares for $103,657.
- EVP Paul Mahon exercised options for 8,300 shares at $146.03 (value: $1.21M) and sold 753 shares for $397,184.
- Director Judy Olian sold 200 shares for $106,000.
- Total open-market sales: ~$1.07 million across four insiders.
- Total derivative exercises: ~$8.1M in value, mostly non-cash events (codes M and A).
- Total value of actual share sales: ~0.0046% of $23.3B market cap, immaterial in scale.
Financial Impact
$1.07 million in open-market insider selling over 7 days, alongside $8.1 million in option exercises. No dilution or direct financial impact from non-cash transactions.
Risk Factors
- Perception risk if investors misinterpret option exercises and sales as negative sentiment, despite being routine for executives with vested options.
- Concentration risk in CEO transactions, Martine Rothblatt accounts for the vast majority of activity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (19 trades, 7d window) | cluster-UTHR-1774470698276 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers